About Mito BioPharm

Mito BioPharm is a start-up mitobiopharmceutical company that focuses on targeting mitochondria and cellular metabolism for development of therapeutics. Mitochondria are at the center of cellular metabolism. Alteration of mitochondrial functions contributes significantly to many diseases such as type II diabetes, neurodegenerative diseases, cancer, and aging in general. It has long been proposed that these diseases could be effectively treated by correcting the aberrant mitochondrial activities. Mito BioPharm has a proprietary technology and lead compounds that embody the therapeutic strategy of “correcting” some mitochondrial functions. The company expects this technology to have major impact on developing novel drugs in these therapeutic areas. One lead compound has shown superior efficacy and safety properties in animal models for treating type II diabetes and hepatic steatosis. The company is initiating IND-enabling studies preparing this compound for clinical trials. Moreover, the medicinal chemistry team and the biology team are collaborating in generating a large pipeline of candidate compounds suitable for other indications such as cancer and neurodegenerative diseases.

 

Founder

Victor Shengkan Jin, Ph.D. is an Associate Professor of Pharmacology at Robert Wood Johnson Medical School of UMDNJ. He also holds joint faculty memberships at the Center for Lipid Research at Rutgers University, the Cardiovascular Institute of New Jersey, and the Cancer Institute of New Jersey. Before joining the faculty of UMDNJ in 2003, Dr. Jin received B.S. in Biological Sciences at Tsinghua University in 1992, received Ph.D. in Pharmacology and Experimental Therapeutics at Cornell University Weill Medical College/Memorial Sloan Kettering Cancer Center in 1999, and completed Postdoctoral training at Rockefeller University in 2002. His research in UMDNJ has been funded by major grants from National Institute on Aging (NIH/NIA), National Cancer Institute (NIH/NCI), Department of Defense (DOD), and American Cancer Society (ACS).   He has served many scientific review panels, including for NIH and for American Cancer Society. Dr. Jin is an internationally recognized expert on research in metabolism and cancer.

 

Investor

Mito BioPharm has secured funding from Mega Base Investment Ltd. The initial investment will fund IND-enabling studies of the lead compound (MT-2), as well as research and development in medicinal chemistry and biology to build up additional drug candidate pipeline. Moreover, milestone triggered investment mechanism for early phases of MT-2 clinical trials has also been established.

 

Legal Counsel

Mito BioPharm has retained the following outside counsel for corporate and intellectual property legal support:

  • Pepper Hamilton, LLP, Pittsburgh, Pennsylvania

 

Management and Key Consultants

  • H Joseph Reiser, Ph.D, President and CEO
  • Victor Jin, Ph.D, Acting CSO and Founder
  • David Augeri, Ph.D, Director of Molecular Design and Synthesis, Rutgers University